Targeted Radiopharmaceuticals Target Selection and Drug Design Summit

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With strong clinical efficacy from blockbuster drugs Pluvicto and Lutathera, radiopharmaceutical leaders are looking for the next application of this highly efficacious and potent modality!

The inaugural Targeted Radiopharmaceuticals Target Selection and Drug Design Summit is your dedicated forum to advancing novel radiopharmaceutical drug discovery. Delve deep into target mining, screening, discovery and selection from ROR1, uPAR, B7-H3, NECTIN-4, CAIX and more. Understand advances in radiobiological, radiodecay and radiation absorption mechanisms to inform optimal targeting strategies from small molecule, peptide, nanobodies, antibody fragments as well as linker and chelator technologies for enhanced PK. Bringing it all together, gain a commercial perspective to enhance your strategic decision-making in target selection and novel drug rationale within this highly dynamic field.

Incorporating key insights from radiopharmaceuticals’ leading drug discovery minds from medicinal chemistry, radiobiology, biology, discovery, R AND D, pharmacology, computational biology, commercial strategy and many more, this is the only global opportunity to gain practical insights into your approaches, from target selection to drug design.

Uniting the discovery experts pioneering the field, join the inaugural TRP Target Selection and Drug Design Summit to understand exactly what targets match the strong therapeutic index of TRPs and uncover optimal targeting strategies for stellar drug discovery!

URLs:
Website: https://go.evvnt.com/2739765-0?pid=176 
Tickets: https://go.evvnt.com/2739765-1?pid=176 
Brochure: https://go.evvnt.com/2739765-3?pid=176 

Time: 9:00 AM - 4:30 PM

Prices:
Drug Developer Conference + Full Workshop Day Ticket: USD 4197.00,
Drug Developer - Conference + 1 Workshop Ticket: USD 3598.00,
Drug Developer - Conference Only Ticket: USD 2999.00,
Academic Conference + Full Workshop Day Ticket: USD 3597.00,
Academic Conference + 1 Workshop Ticket: USD 3098.00,
Academic - Conference Only Ticket: USD 2599.00,
Service Provider Conference + Full Workshop Day Ticket: USD 5097.00,
Service Provider Conference + 1 Workshop Ticket: USD 4398.00,
Service Provider - Conference Only Ticket: USD 3699.00

Speakers: Alison Armour, Founder Curadh pharmaceuticals, CURADH Pharmaceuticals, Amrik Basran, CSO, CURADH Pharmaceuticals, Andreas Goutopoulos, CEO, actithera, Andrew Cittadine, Chief Operating Officer, Monopar Therapeutics, Chandler Robinson, CEO, Monopar Therapeutics, Daniel Steiner, Senior VP, Oncology Research, Molecular Partners AG, David Ulmert, Director, University of California Los Angeles, Frank Comer, Director, Tumor Targeted Delivery, Early Oncology Discovery, AstraZeneca, Jack Hoppin, CEO, Ratio Therapeutics, John Bullen, Associate Director, AstraZeneca, Jonathan Young, Chief Scientific Officer, WARF Therapeutics, Wisconsin Alumni Research Foundation, Quaovi Sodji, Assistant Professor, University of Wisconsin-Madison, Reinier Hernandez, Assistant Professor, University of Wisconsin-Madison, Riccardo Canevari, CEO, RadioPharm Theranostics, Sudhakar Chintharlapalli, Vice President and Head of Biology and Translational, Rayzebio, Zachary Morris, Chair and Paul Harari Professor of Human Oncology, University of Wisconsin-Madison